Morphinsulfat Retard Heumann (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Morphinsulfat Retard Heumann, is an opioid analgesic presented as a prolonged‑release oral formulation for oral use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Morphinsulfat Retard Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine Sulfate acts on the central nervous system to alleviate pain associated with several clinical conditions.

- Moderate to severe acute pain: provides rapid and effective analgesia. - Post‑operative pain: controls pain following surgical procedures. - Cancer‑related pain: reduces malignant disease‑associated discomfort. - Chronic non‑cancer pain: manages persistent severe pain when other treatments fail.

Morphine Sulfate may cause a range of adverse reactions, from mild to severe, depending on dose and patient factors.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dizziness: sensation of light‑headedness or unsteadiness. - Dry mouth: reduced salivation leading to throat discomfort. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing faintness. - Profound sedation: extreme drowsiness impairing consciousness. - Addiction or dependence: compulsive use despite harmful consequences. - Withdrawal syndrome: symptoms occurring after abrupt discontinuation. - Anaphylaxis: rare severe allergic reaction with rash, swelling, and airway compromise.

Before prescribing Morphine Sulfate, clinicians should consider several safety measures.

- Pain assessment: verify that pain severity justifies opioid therapy. - Organ function: evaluate renal and hepatic status to adjust dosing. - Respiratory monitoring: watch for signs of respiratory depression, especially after dose initiation. - Concomitant CNS depressants: avoid or limit use with benzodiazepines, barbiturates, or alcohol. - Elderly patients: start with lower doses and monitor closely for adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Morphine Sulfate can interact with other medications, altering its safety or effectiveness.

Major Interactions (Avoid): - Other opioids: additive respiratory depression and sedation. - Benzodiazepines: increased risk of profound CNS depression. - MAO inhibitors: potential for severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine): can affect metabolism and efficacy. - Antihistamines: may enhance sedative effects.